🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million instances annually. Especially elevated rates are reported in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, the spread of superbugs and the highly restricted therapeutic options currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The study involved over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in many developing nations.

Clinicians directly involved have expressed hope. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is viewed as vital to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea globally.